857970-06-0

Basic information

• Product Name: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-
• Synonyms: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-;6-Bromothiazolo[4,5-b]pyridin-2-amine
• CAS NO: 857970-06-0
• Molecular Formula: C6H4BrN3S
• Molecular Weight: 230.08506
• Mol File: 857970-06-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 362.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.950±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: -0.33±0.50(Predicted)
• CAS DataBase Reference: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(857970-06-0)
• EPA Substance Registry System: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(857970-06-0)

Safety Data

• Hazardous Substances Data: 857970-06-0(Hazardous Substances Data)

Usage

General Description

Thiazolo[4,5-b]pyridin-2-amine, 6-bromo- is a chemical compound with the molecular formula C8H6BrN3S. It is a brominated derivative of thiazolo[4,5-b]pyridin-2-amine, which is a heterocyclic compound containing a thiazole ring fused to a pyridine ring. This chemical is commonly used in pharmaceutical research as a building block for the synthesis of various organic compounds, including potential drug candidates. The presence of the bromine atom in its structure may impart specific properties and reactivity to the compound, making it useful for the development of novel pharmaceuticals or materials with specialized functions.

InChI:InChI=1S/C6H4BrN3S/c7-3-1-4-5(9-2-3)10-6(8)11-4/h1-2H,(H2,8,9,10)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 15192-76-4 copper(II) thiocyanate 
• 35486-42-1 2-amino-3,5-dibromopyridine 
• 31545-35-4 1-(3,5-dibromopyridin-2-yl)thiourea 
• 31430-58-7 N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide 
• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 588729-97-9 N-(6-bromo[1,3]thiazolo[4,5-b]pyridin-2-yl)benzamide 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 960535-44-8 6-bromo-2-chlorothiazolo[4,5-b]pyridine 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.